I’m on drugs. And so are you. There
are drugs that society can ostensibly do without, but a handful are so vital
that they are literally keeping some of us alive today. In between the natural
world and the medicine cabinet, biotechnology is making life-saving drugs more effective,
affordable, and widely available. This is the story of one blockbuster drug,
and how it benefitted from observations in a very unusual laboratory. The drug is Pembrolizumab. It’s sold under
the brand name Keytruda and has become the cornerstone of modern cancer
immunotherapy.
Our immune systems are designed to
fight infections and disease, including cancer.
A class of white blood cells called T-lymphocytes or T-cells, is the
immune system’s weapon that destroys pathogens like viruses and cancer cells (Cleveland Clinic, 2023). The cancerous cells
of some solid tumors incorporate a gene known as CD274 (Wikipedia, 2026). Expression of this gene produces a cellular
transmembrane protein called the Programmed Death-1 Ligand (PD-L1). PD-L1
interacts with the PD-1 immune checkpoint, a regulatory protein in T cells. Unchecked,
this interaction allows cancer cells to shield themselves from T cell attack (Lighter Side of Cancer, 2019). Inhibiting the PD-1
immune checkpoint, as illustrated below, is the basis of Keytruda immunotherapy.
Researchers at

Figure 1: In this
cell-level illustration, Pembrolizumab inhibits the PD-1 immune checkpoint, blocking PD-L1, and activating the T-cell which
results in an immune system response to the cancer. (Source: Ross RC, Akinde YM, Schauer PR, le
Roux CW, Brennan D, Jernigan AM, Bueter M, Albaugh VL., CC BY 4.0
<https://creativecommons.org/licenses/by/4.0>, via Wikimedia Commons)
the Dutch pharmaceutical company Organon started work on a
PD-1 inhibitor in 2003. After two corporate acquisitions, Organon’s PD-1
antibody found its way into Merck’s oncology portfolio in 2009 (Wikipedia, 2025). In 2013, the FDA
designated Keytruda a Breakthrough Therapy. This accelerated the federal review
process and led to Keytruda’s FDA approval in 2014 as the first anti-PD-1
cancer therapy available in the US. Keytruda was subsequently approved for
treatment of metastatic non-small cell lung cancer in 2015 (Bhateja, 2016) and has since expanded to treat a long
list of cancers, including head, neck, bladder cancer, and more.
Historically, Keytruda has been administered
to patients by an intravenous infusion (U.S. Food & Drug Administration). Treatment takes
approximately thirty minutes with the patient seated in a chemotherapy clinical
setting (Lighter Side of Cancer, 2019). Shortly after FDA
approval, Merck sought a new formulation of Keytruda that can be delivered by
subcutaneous injection, like a vaccine. Subcutaneous delivery would allow
patients to self-administer with a spring-loaded syringe, freeing them from the
travel burden and time commitment of the intravenous infusion sessions (Kim, 2022). The original
Keytruda formulation was too thick and syrupy to push through a small gauge
syringe. A less viscous formulation was necessary. A common approach to subcutaneous
delivery is formulating the drug as a crystalline suspension. Neutral Protamine
Hagedorn (NPH) insulin, an FDA-approved diabetes drug, is a prime example. Microscopic
crystals of insulin protein, binding agents, and preservatives are suspended in
an aqueous buffer of water and salts that maintain correct pH and isotonicity (FDA Report, 2026). The suspension is
the appropriate viscosity for subcutaneous injection and promotes an extended
systemic drug exposure (Drug Bank, 2026). For Keytruda, the key was to come up
with a formula that yields crystals of the right size and uniformity. Identifying
the conditions for optimal crystallization could take months or years, testing myriad
combinations of the 48 known independent process variables – unless there was a
shortcut (Reichert, 2019).
During the 1980s, the National
Aeronautics and Space Administration initiated the Protein Crystal Growth (PCG)
program to test the hypothesis that protein crystals grown in microgravity would
be free from dislocations and other lattice defects caused by sinking of
heavier components (sedimentation), gravity-induced fluid flows, and other effects
(Long, 1992).
The crystal lattice could advance uniformly, driven exclusively by diffusion (McPherson, 2015). The first crystal
growth experiment flew in the European Spacelab 3 module aboard Space Shuttle
Challenger mission STS-51B in April 1985 (Wikipedia, 2025). NASA replaced these temporary experiments with
the more permanent Space Shuttle Protein Crystallization Facility (PCF) in the
1990s. PCF growth trials during the 1998 STS-95 mission of Space Shuttle Discovery
yielded insulin crystals that were thirty-four times larger on average than a
terrestrially-grown control (Borgstahl, 2001). Larger protein crystals are prized by drug
researchers for determining the three-dimensional structure of complex proteins
via x-ray crystallography, a major biophysical method used by structural
biologists to better understand the protein structural-functional relationship.
Larger crystals diffract x-rays with greater resolution and signal to noise
ratio (referred to as I/sigma ratio) than smaller crystals, making it easier to
solve the protein’s molecular structure (McPherson, 2015). From then on, protein crystal growth in
space became a pharmaceutical cottage industry. Pictured below is a variety of
protein crystals grown on orbit. Facilities were commissioned aboard Space
Station Mir, and eventually, the International Space

Figure 2: Protein
crystals grown on the US Space Shuttle and Russian Mir space station (Source: NASA
Marshall Space Flight Center (NASA-MSFC), Public domain, via Wikimedia Commons)
Station (ISS). As of 2022, the ISS has
run over 500 protein crystallization experiments and the number continues to
climb (Kim, 2022).
Merck began sponsoring ISS microgravity crystallization work in the early 2000s
and in February 2017, Keytruda was ferried to the ISS by the SpaceX Commercial
Re-Supply Service 10 mission (Reichert, 2019). At this point in the story, it’s
important to pause and restate the primary benefits of protein crystallization
in microgravity, as summarized by Jackson: larger, crystals with fewer defects
and greater x-ray diffraction resolution (Jackson, 2024). What’s more, it works for a wide range
of molecularly intricate proteins, including enzymes, cellular membrane
proteins, and antibodies that are fiendishly difficult candidates for
crystallization on earth. However, bigger crystals were not what Merck
was looking for in a low-viscosity injectable formulation. In fact, they needed
the opposite: a uniform distribution of smaller crystals. How would they
achieve this in microgravity crystallization experiments? Fortunately, scientists
had made a seminal observation during the space shuttle PCF era a quarter of a
century earlier and it would be the key to the new formulation.
In 2009,
Merck merged with the American pharmaceutical company Schering-Plough, perhaps
best known for the blockbuster allergy medicine Claritin (Wikipedia, 2024). The merged company did business under
the name Merck Sharp & Dome (MSD) (Reichert, 2019). During the early 90s, Schering-Plough
sponsored space shuttle PCF experiments. Pertinent to this story was a
crystallization experiment aimed at reformulating the hepatitis C drug
interferon alpha-2b (brand name Intron A) for low viscosity subcutaneous
delivery that was run during the Space Shuttle Discovery STS-70 mission in July
1995 (Reichert, 2019), (Wikipedia, 2025). The PCF process that
was employed is known as Temperature Induced Batch Crystallization (McPherson, 2015). TIBC starts with supersaturated
protein buffer solution sample that is prepared on the ground. Once on orbit,
crystallization begins when the solution temperature is cycled up or down
according to a programmed profile that may include periods of constant
temperature (dwells) to yield desired crystal properties. (McPherson, 2015). Protein solubility changes with temperature,
and crystals nucleate by diffusion in microgravity over days or weeks, a much
longer period than on earth (Reichert, 2019). The Merck team would refer to the
Intron A TIBC protocol in the ISS Keytruda crystallization experiments.
The 2017 Keytruda TIBC experiment
started on the ground prior to launch. Researchers prepared the experimental
solution with supersaturated protein in a buffer with polyethylene glycol PEG (Reichert, 2019). It was loaded into a lot of 1-ml non-conductive
polysulfone vials, each sealed with an aluminum cap. Sealed vials were stacked
and assembled in the cylinders that comprise the ISS PCF. Detailed photos of
PCF reaction cylinders are on display at the ISS National Laboratory website (Protein
Crystallization Facility - ISS National Lab). On board the ISS, the
cylinders were loaded in the Microgravity Experiment Research Locker Incubator
(MERLIN, pictured below), where they remained
Figure 3: Microgravity
Experiment Research Locker Incubator (MERLIN, Source: NASA, Public domain, via
Wikimedia Commons)
for 18 days (Reichert, 2019). The stacked vials form a continuous circuit that conducts heat between the baseplate of the cylinder and the opposite end of the stack. This allowed the MERLIN process controller to ramp the
temperature of multiple vial stacks from 4-30C over 48 hours (Reichert, 2019). Following the
experiment, the vials were returned to earth on board the SpaceX Dragon capsule
in a cargo container maintained at 22C. Crystal samples from the ISS vials
were compared to samples from a control experiment run on the ground. Viscosity measurements of crystalline
suspension samples from the ISS and ground experiments showed that, as
expected, the ISS suspension was over 30% less viscous (Reichert, 2019). Results of a comparison of crystal
size was compelling. A histogram of the distribution of protein crystal size
from the ground control experiment revealed two distinct peaks, one at 13
micrometers and the other at 102 (a bimodal distribution). The histogram from
the flight experiment had only one peak at 39 micrometers. Clearly, crystallizing
Keytruda in microgravity yielded a more uniform distribution of small crystals.
Microgravity
crystallization trials of Keytruda revealed two factors that are required to
replicate the desired suspension on earth: suppressing sedimentation and applying
engineered temperature gradients. Was the ISS trial worth the hassle? To this
question, Reichert remarks that “microgravity research offers researchers an
opportunity to generate materials distinct from classical earth-based
experiments and provide unexpected results that can change the design and
planning of earth-based experiments and processes” (Reichert, 2019). With
the help of microgravity, the Keytruda formulation for subcutaneous delivery
was FDA approved in 2025 (Wikipedia, 2025). The story of Keytruda is only one
chapter in a long history of pharmaceutical research in outer space, and the
future is bright. Microgravity protein crystallization experiments have outlived
the generations of orbital laboratory studies, and it will likely continue in
future trials on commercial space stations beyond the 2030 retirement of the
ISS.
The author is grateful to Dr. Christopher Kane for his
contribution to this post.
References
American Diabetes Association. (2019, July 1). Diabetes
Day by Day: The History of a Wonderful Thing We Call Insulin. Retrieved
from American Diabetes Association:
https://diabetes.org/blog/history-wonderful-thing-we-call-insulin
Bhateja, P. (2016, February). Pembrolizumab in
Non-Small Cell Lung Cancer. Journal of Targeted Therapies in Cancer, 5(1).
Borgstahl, G. e. (2001, January 12). A Test of
Macromolecular Crystallization in Microgravity: Large, Well-Ordered Insulin
Crystals. NASA NTRS. Retrieved from
https://ntrs.nasa.gov/citations/20010084630
Cleveland Clinic. (2023, January 17). T Cells.
Retrieved from Cleveland Clinic:
https://my.clevelandclinic.org/health/body/24630-t-cells
Cleveland Clinic. (2024, January 17). Insulin.
Retrieved from Clevaland Clinic:
https://my.clevelandclinic.org/health/body/22601-insulin
Drug Bank. (2026). NPH Insulin. Retrieved
from Drug Bank: https://go.drugbank.com/salts/DBSALT001734
FDA.Report. (2026). HUMULIN N- insulin human
injection, suspension STERILE DILUENT- diluent injection, solution.
Retrieved from FDA.Report:
https://fda.report/DailyMed/f6edd793-440b-40c2-96b5-c16133b7a921
Jackson, K. e. (2024, July 16). An Analysis of
Protein Crystals Grown under Microgravity Conditions. Crystals, 14(7).
Retrieved from https://doi.org/10.3390/cryst14070652
Kim, S. (2022, November 13). Pharma goes to
space: Researchers are capitalizing on microgravity in space to accelerate
drug discovery and development. Retrieved from Chemical and Engineering
News:
https://cen.acs.org/pharmaceuticals/drug-development/Pharma-goes-space-drug-development/100/i40
Lighter Side of Cancer. (2019). How Keytruda
Cancer Treatment Works (Update). Retrieved from YouTube:
https://www.youtube.com/watch?v=R0ccmAXq4RU
Long, M. (1992, January 1). Large scale
crystallization of protein pharmaceuticals in microgravity via temperature
change. NASA NTRS. Retrieved from
https://ntrs.nasa.gov/citations/19930013459
Long, M. e. (1994, July). Protein crystal growth in
microgravity-temperature induced large scale crystallization of insulin. Microgravity
Sci Technol, 7(2), 196-202.
McPherson, A. a. (2015). Microgravity Protein
Crystallization. NPJ Microgravity, 1. Retrieved from
https://www.nature.com/articles/npjmgrav201510
Muley, A. (2024, June 24). Keytruda Receives 40th
FDA Approval. Retrieved from Cancer Research Institute:
https://www.cancerresearch.org/blog/keytruda-receives-40th-fda-approval
Reichert, P. e. (2019). Pembrolizumab microgravity
crystallization experimentation. npj Microgravity, 28(5).
doi:https://doi.org/10.1038/s41526-019-0090-3
U.S. Food & Drug Administration. (n.d.). Medication
Guide, KEYTRUDA. Retrieved 3 2026, from
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s188lbl.pdf#page=181
Wikipedia. (2024, October 16). Schering-Plough.
Retrieved from Wikipedia: https://en.wikipedia.org/wiki/Schering-Plough
Wikipedia. (2025, December 24). Pembrolizumab.
Retrieved from Wikipedia: https://en.wikipedia.org/wiki/Pembrolizumab
Wikipedia. (2025, April 20). STS-51-B.
Retrieved from Wikipedia: https://en.wikipedia.org/wiki/STS-51-B
Wikipedia. (2025, July 22). STS-70. Retrieved
from Wikipedia: https://en.wikipedia.org/wiki/STS-70
Wikipedia. (2026, January). PD-L1. Retrieved
from Wikipedia: https://en.wikipedia.org/wiki/PD-L1
Comments
Post a Comment